Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: vaccine trial + dna vaccine + vical  Related to the article below (Last Update: 5/12/2008)

Therapeutic DNA Vaccine Company Inovio Biomedical Reports First ...
WELT ONLINE, Germany - May 9, 2008
Corporate Update The operational highlights for the first quarter included the results reported by our partners from ongoing DNA vaccine clinical studies, ...INO
Vical Reports First Quarter 2008 Financial Results and Updates Key ...
Earthtimes (press release), UK - May 8, 2008
The trial is being funded by cash payments and equity investments from AnGes MG, Inc. -- The company's Phase 2 trial of a vaccine designed to prevent ...VICL - EPA:SAN
Source: Google News

… immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult … -
TP Le, KM Coonan, RC Hedstrom, Y Charoenvit, M … - Vaccine, 2000 - Elsevier
... Despite induction of excellent CTL responses, intramuscular DNA vaccination via
needle injection failed ... Keywords: DNA vaccine; Malaria; Clinical trial ...

Immunogenicity of a Plasmid DNA Vaccine Encoding Chimeric Idiotype in Patients with B-Cell Lymphoma … -
JM Timmerman, G Singh, G Hermanson, P Hobart, DK … - Cancer Research, 2002 - AACR
... BT, RR, CBC, AvB, RL], and Vical Corporation, San ... application of patient-specific
Id vaccines to the ... guide the design of such future Id DNA vaccine trials. ...

Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine -
R Wang, DL Doolan, TP Le, RC Hedstrom, KM Coonan, … - Science, 1998 - sciencemag.org
... a P. yoelii circumsporozoite protein DNA vaccine elicits a ... Four vaccine formulations
were stored as 1.0-ml ... phase I safety and immunogenicity trial in healthy ...

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection … -
TJ Kochel, K Raviprakash, CG Hayes, DM Watts, KL … - Vaccine, 2000 - Elsevier
... DNA candidate vaccines against dengue-2 [11], Murray Valley ... DNA injection, serum
collection and virus challenge. Vaccine trial na?ve, adult male and female A ...

DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine … -
DL Doolan, SL Hoffman - International Journal for Parasitology, 2001 - Elsevier
... and subsequent studies, subsequent trials will evaluate ... International Development
Malaria Vaccine Development Program ... merozoite surface protein 1 DNA vaccines. ...

… with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine -
M Sedegah, TR Jones, M Kaur, R Hedstrom, P Hobart, … - Proceedings of the National Academy of Sciences of the …, 1998 - pubmedcentral.nih.gov
... recently initiated a Phase I clinical trial of a P ... afforded by the PyCSP DNA vaccine,
we assessed sequential immunization with DNA, recombinant vaccinia ...

Malaria vaccine developments -
VS Moorthy, MF Good, AVS Hill - The Lancet, 2004 - Elsevier
... Candidate malaria vaccines in clinical trials. ... de Manhica [CISM], Mozambique) Malaria
Vaccine Development Unit ... Pf-EXP-1, Pf-LSA-3 (DNA vaccines), Pre-erythrocytic ...

Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine -
R Wang, J Epstein, FM Baraceros, EJ Gorak, Y … - Proceedings of the National Academy of Sciences, 2001 - National Acad Sciences
... pox; the staff of the Clinical Trial Center at ... & Druilhe, P. (1996) in Malaria Vaccine
Development, ed ... in Developments and Clinical Progress of DNA Vaccines, eds ...

A DNA vaccine protects mice against the rickettsial agent Cowdria ruminantium -
P Immunology - Parasite Immunology, 1998 - Blackwell Synergy
... Inactivated, cell culture-derived C. ruminantium vaccines which incorporate ... into
a eukaryotic expression vector VCL1010 (Vical, San Diego ... DNA vaccine Trial 1. ...

DNA vaccines?back in the saddle again? -
K Powell - Nature Biotechnology, 2004 - nature.com
... Rounding the bend The trend toward testing DNA vaccines as part of a combination
trial can be seen in both the large vaccine producers like Merck, in ...

Source: Google Scholar

Vical Reaches Initial Enrollment Milestone In Phase 2 Trial Of DNA Vaccine Against CMV
Vical Incorporated (Nasdaq: VICL) today announced the enrollment of the 20th hematopoietic stem cell transplant recipient in the company's Phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). After the 20th recipient's two-month follow-up visit, an independent data safety monitoring board will conduct an interim evaluation of safety data for all subjects enrolled in the trial.

"We are pleased that recent protocol amendments have accelerated patient enrollment in our CMV vaccine trial," said Ronald B. Moss, M.D., Vice President of Clinical Development at Vical, "and we hope to sustain the momentum by continuing to enroll additional patients as safety data are being collected and evaluated. Our novel immunotherapeutic vaccine may address the serious healthcare problem of CMV reactivation for transplant patients, and could eventually be useful in preventing birth defects caused by CMV infection of pregnant women."
The double-blind, placebo-controlled Phase 2 trial was designed to compare safety of the vaccine against placebo in approximately 80 matched, related donor/recipient pairs scheduled for hematopoietic stem cell transplants. Subsequent protocol amendments intended to provide additional scientific insights and speed up trial enrollment include a more convenient donor vaccination schedule and vaccination of recipients only. Because most recipients are expected to face a natural viral challenge as pre-existing CMV infection reactivates under immunosuppression, the primary efficacy endpoint is the occurrence rate of clinically significant CMV levels in patients receiving vaccine compared with patients receiving placebo. Other important endpoints include immune responses against the specific CMV features targeted by the vaccine.

About CMV

CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries. While a healthy immune system typically protects an infected person against CMV disease, it rarely succeeds in completely eliminating the infection, and those whose immune systems are not fully functional are at high risk of CMV proliferation, potentially leading to severe illness or death. These include transplant patients who take immunosuppressive drugs, and fetuses and newborns of mothers who first become infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.
About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether the company will initiate the Phase 2 trial at leading transplant centers and successfully enroll 80 matched, related stem cell transplant donor/recipient pairs in a timely manner, if at all; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and recipients; whether the company will expand development of a CMV vaccine to address prevention of congenital disease; whether the vaccine will induce both antibody and cellular immune responses; whether the vaccine will prevent clinically significant CMV levels; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Vical Incorporated
http://www.vical.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.